New Adeno-Associated Virus Capsids for Gene Therapy
This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.
Patent Number
US 11357868
Status
Active
Filing Date
October 12, 2021
Grant Date
June 14, 2022
Expiration
October 12, 2041
Claims
16
Assignee
University of Pennsylvania
Inventors
James M. Wilson, Mauricio R. Alvira, Guangping Gao, Luc H. Vandenberghe
Citations
1 forward · 41 backward
What it covers
This patent is about creating specialized tools for gene therapy. It claims specific versions of adeno-associated virus (AAV) capsids, which are like protective shells for delivering genetic material. Specifically, it describes cultured host cells that contain engineered DNA (recombinant nucleic acid molecules) designed to produce these new AAV capsids, named AAVhu37. These DNA molecules also carry a gene that is not from AAV (a heterologous non-AAV sequence), intended for therapeutic use. The patent details how these engineered cells, when containing specific parts of the AAVhu37 capsid protein sequence (like vp1, vp2, or vp3) and a 'rep gene' (which helps the virus replicate), can be used to produce gene therapy vectors. For example, a cell might be engineered with a plasmid containing the DNA for the AAVhu37 vp1 capsid protein and a therapeutic gene, along with a rep gene from AAV2.
What it doesn't cover
- —Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.
- —Does not cover the use of these AAV vectors in a living organism, only in cultured host cells.
- —Does not cover the rep gene being from a source other than AAV2 if claim 3, 6, or 9 is considered.
- —Does not cover the recombinant nucleic acid molecule being something other than a plasmid.
- —Does not cover the heterologous non-AAV sequence being identical to an AAV sequence.
The clever bit
The innovation lies in identifying and defining specific novel sequences for AAV capsid proteins (AAVhu37) that can be engineered into vectors for gene delivery. This allows for potentially more targeted or efficient delivery of therapeutic genes compared to previously known AAV types.
Why it matters
Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.
Real-world examples
- 1.Research laboratories developing gene therapy vectors
- 2.Biotechnology companies creating new treatments for genetic diseases
Generated by PatentBrief · Not legal advice · patentbrief.org
US 11357868 · 2026